Updating Risks and Benefits in Phase I Oncology Trials

更新第一阶段肿瘤学试验的风险和益处

• 批准号: 6825894
• 负责人: Christine P Grady
• 金额: --
• 依托单位: CLINICAL CENTER
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/6825894
• 关键词: clinical trial phase I; drug adverse effect; health surveys; human data; human mortality; interview; meta analysis; neoplasm /cancer; outcomes research; questionnaires; therapy adverse effect; vital statistics

This study is a meta-analysis of the responses and toxic death rates of all phase I oncology studies initiated between 1991 and 2002 and sponsored by CTEP/NCI. The goal is to update our understanding of responses and toxicities in Phase I oncology trials. A second goal is to describe the diversity of phase I oncology trials and to show that relying on a single value to understand response or toxicity is misleading.

本研究是对 1991 年至 2002 年间发起并由 CTEP/NCI 赞助的所有 I 期肿瘤学研究的反应和中毒性死亡率的荟萃分析。目标是更新我们对 I 期肿瘤学试验中的反应和毒性的理解。第二个目标是描述 I 期肿瘤学试验的多样性，并表明依靠单一值来理解反应或毒性是误导性的。